Welcome to our dedicated page for Aptose Bioscienc SEC filings (Ticker: APTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aptose Biosciences Inc. (APTO) SEC filings page provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K and other key documents. As a Canadian issuer with securities previously registered in the United States, Aptose uses these filings to report material events, financing arrangements, clinical milestones, and governance changes related to its precision oncology business.
Aptose describes itself in its filings as a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy for newly diagnosed acute myeloid leukemia (AML). Forms 8-K include updates on clinical trial progress, such as developments in the TUSCANY Phase 1/2 study of the TUS+VEN+AZA triplet, as well as financial and capital structure events like loan facility agreements, interest deferral arrangements with Hanmi Pharmaceutical, reverse share split plans, and committed equity and at-the-market facilities.
Regulatory filings also document auditor transitions and shareholder votes. For example, Aptose has filed reports on its prior auditor’s decision not to stand for re-appointment, the competitive selection process that led to the appointment of a new independent registered public accounting firm, and shareholder approval of that appointment. Other filings discuss material weaknesses in internal control over financial reporting related to complex financial instruments, providing context on the company’s reporting environment.
A notable document on this page is the Form 25 filed by Nasdaq Stock Market LLC, which serves as a notification of removal of Aptose’s common shares from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934. This filing identifies Nasdaq as the exchange and common shares as the affected class of securities, indicating a change in the company’s exchange listing status.
Through Stock Titan, users can review these filings alongside AI-powered summaries that highlight important sections, explain technical language, and surface items such as clinical disclosures, financing terms, auditor changes, and listing-related notices. Real-time updates from EDGAR ensure that new 8-Ks and other reports appear promptly, while structured access helps readers locate information about material agreements, direct financial obligations, and governance decisions without parsing full-length documents manually.
Aptose Biosciences (NASDAQ:APTO) filed an 8-K disclosing a new US$8.5 million secured term loan agreement with Hanmi Pharmaceutical dated 20 Jun 2025.
Key terms:
- Facility available in up to 5 advances (≤US$2.5 m each) through 31 Dec 2025; non-revolving.
- Interest: 6% fixed; balloon repayment of all principal and accrued interest on 31 Aug 2028.
- Secured by first-ranking liens on all present and after-acquired property of Aptose and guaranteed by subsidiaries.
- Purpose limited to continued clinical development and operating costs related to Tuspetinib, an AML therapy.
- Contains customary covenants and default provisions; any re-borrowings prohibited.
The filing also triggers Item 2.03 for creation of a direct financial obligation. The debt adds leverage but supplies non-dilutive capital for ongoing trials.
Aptose Biosciences Inc. (NASDAQ: APTO) filed a Form 8-K dated June 20, 2025 to disclose an Item 7.01 Regulation FD communication. The filing states that the company issued a press release on the same date, attached as Exhibit 99.1.
The 8-K expressly notes that, under General Instruction B.2, the press release is being “furnished” rather than “filed”, meaning it is not incorporated into Exchange Act reports unless specifically referenced. No financial results, strategic transactions, or operational updates are contained in the 8-K itself, and the exhibit text is not included in the filing excerpt provided.
Aptose Biosciences Inc. (APTO) filed a Form 8-K dated June 18, 2025 to disclose the immediate resignation of director Carol Ashe, effective June 16, 2025.
The company states that Ms. Ashe’s departure was not related to any disagreement regarding operations, policies, or practices. Chairman, President & CEO William G. Rice, Ph.D. signed the filing on behalf of the board. No other management changes, financial data, or strategic transactions were reported.